73Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Hong Kong
Neuroscience Intelligence
Hong Kong neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #39 of 50 · Data maturity A · Research score 30.9 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
25Recruiting trials
59Publications
9Institutions
Executive interpretation
Hong Kong ranks #39 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
The Hong Kong Polytechnic University199 recruiting
Chinese University of Hong Kong172 recruiting
The University of Hong Kong136 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.50 recruiting
Merck Sharp & Dohme LLC32 recruiting
Education University of Hong Kong31 recruiting
Hoffmann-La Roche20 recruiting
Shionogi10 recruiting
Tseung Kwan O Hospital, Hong Kong11 recruiting
UCB BIOSCIENCES, Inc.10 recruiting
Disease activity
Autism12trials
Depression9trials
Alzheimers9trials
Adhd8trials
Stroke8trials
Epilepsy6trials
Parkinsons5trials
Schizophrenia4trials
Neuro Oncology3trials
Dementia Other3trials
Research institutions
Chinese University of Hong KongOpenAlexlinked institution
Lingnan UniversityOpenAlexlinked institution
Princess Margaret HospitalOpenAlexlinked institution
Hong Kong Polytechnic UniversityOpenAlexlinked institution
Hong Kong University of Science and TechnologyOpenAlexlinked institution
City University of Hong KongOpenAlexlinked institution
Hong Kong Baptist UniversityOpenAlexlinked institution
Lui Che Woo Institute of Innovative MedicineOpenAlexlinked institution
University of Hong KongOpenAlexlinked institution
Clinical evidence trail
NCT07782177Optimizing Elderly Hearing Loss Care in Hong Kong A Cost-Effectiveness and Satisfactory Analysis of a Pilot Collaborative Model Between Otorhinolaryngologists and Family Medicine SpecialistsNOT_YET_RECRUITING
NCT07779863Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's DiseaseNOT_YET_RECRUITING
NCT07747181The Effect of Combined Brain Stimulation and Yoga for Improving Cognitive Function in PsychosisRECRUITING
NCT07647900Photography-Based Intervention for Children With Attention Deficit Hyperactivity DisorderACTIVE_NOT_RECRUITING
NCT07441928Effects of Smoking on Network Connectivity in Patients With Schizophrenia Symptoms in Scz PatientsRECRUITING
NCT07392632MindfulCityU-- A Mindfulness Mobile Application for Promoting University Students' Mental HealthNOT_YET_RECRUITING
NCT07382336A Mobile Application for Early Detection and Symptoms Trajectories of Postpartum Depression Using Ecological Momentary Assessment (EMA)RECRUITING
NCT07308210Hybrid Computerized EF Training Using Virtual Human Stimuli for AutismACTIVE_NOT_RECRUITING
NCT07252739KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RECRUITING
Research evidence trail
PUBMEDDeconstructing the heterogeneity of adolescent social anxiety: A cognitive diagnostic approach from a sex perspective.2027-01-01
PUBMEDAssociation between lithium treatment and vascular calcification in bipolar disorder: A retrospective cohort study.2026-12-15
PUBMEDA short-term high-fat diet induced acute postoperative pain priming through impairing SerpinB6 protein-mediated M2 macrophage polarization.2026-11-15
PUBMEDThe impact of insomnia and excessive daytime sleepiness on depression and suicidal ideation in adolescents: A three-year longitudinal study.2026-11-01
PUBMEDCorrigendum to "Evolving patterns of antipsychotic use and polypharmacy for schizophrenia in Hong Kong: a 21-year longitudinal study" [Psychiatry Research 364 (2026) 117346].2026-11-01
PUBMEDPatterns, predictors and outcomes of the joint trajectories of positive and negative symptoms in patients with early psychosis: 12-year follow-up of the randomized controlled trial on extended early intervention.2026-11-01
PUBMEDReinforcement learning deficits in at-risk mental state for psychosis: the role of primary negative symptoms.2026-10-17
PUBMEDDecomposing the intersectional cognition inequalities among chinese older adults: evidence from a 20-year longitudinal survey in China.2026-10-16
PUBMEDHabitual Diet, Gut Microbiome Dysbiosis, and α-Synucleinopathy Conversion in Isolated Rapid Eye Movement (REM) Sleep Behavior Disorder.2026-10-16
PUBMEDAssociations of one-to-one peer support service and intervention outcomes among older adults with depressive symptoms: Evidence from a community-based stepped care programme for late-life depression in Hong Kong.2026-10-12
PUBMEDGenome-wide analysis of common structural variants in Alzheimer's disease identifies a risk-associated regulatory CCG repeat in FAM193B.2026-10-12
PUBMEDApplication of IgA-Seq in schizophrenia to identify key gut bacteria that promote abnormal behavior in mice.2026-10-07
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.